Status:
RECRUITING
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Lead Sponsor:
Wei Zhao
Collaborating Sponsors:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions:
Hematological Neoplasms
Eligibility:
All Genders
1-18 years
Phase:
PHASE4
Brief Summary
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Detailed Description
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs based on the opportunistic sampling strategy in ...
Eligibility Criteria
Inclusion
- Patients must be diagnosed with hematological neoplasms
- Antineoplastic drugs or anti-infective drugs used as part of regular treatment
Exclusion
- expected survival time less than the treatment cycle;
- patients with other factors that researcher considers unsuitable for inclusion.
Key Trial Info
Start Date :
January 31 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT03844360
Start Date
January 31 2016
End Date
December 31 2026
Last Update
March 30 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221000
2
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tanjin, Tianjin Municipality, China, 300020